Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
详细信息 查看全文
- 作者：Deborah M. Stephens ; Amy S. Ruppert ; Kami Maddocks ; Leslie Andritsos ; Robert Baiocchi ; Jeffrey Jones ; Amy J. Johnson ; Lisa L. Smith ; Yuan Zhao ; Yonghua Ling ; Junan Li ; Mitch A. Phelps ; Michael R. Grever ; John C. Byrd ; Joseph M. Flynn
- 关键词：B2M ; beta 2 microglobulin ; CAR ; cyclophophamide ; alvocidib ; rituximab ; CDK ; cyclin-dependent kinase ; CLL ; chronic lymphocytic leukemia ; CR ; complete response ; CRS ; cytokine release syndrome ; DLT ; dose limiting toxicity ; ECOG ; Eastern Cooperative Oncology
- 刊名：Leukemia Research
- 出版年：2013
- 出版时间：October, 2013
- 年：2013
- 卷：37
- 期：10
- 页码：1195-1199
- 全文大小：425 K
文摘
Alvocidib has demonstrated efficacy in high-risk chronic lymphocytic leukemia (CLL) patients. In this phase I study, we combined cyclophosphamide, alvocidib and rituximab (CAR) in a schema designed to mitigate tumor lysis syndrome (TLS) seen previously with alvocidib. Nine nucleoside analog-na?ve, high-risk patients received escalating doses of CAR therapy. Dose limiting toxicity was not experienced. No instances of TLS were observed. Patient responses included three complete remissions and four partial remissions. CAR was tolerable and active in high-risk CLL patients without TLS toxicity. With continued monitoring of toxicities, a phase Ib/II study of this combination as frontline therapy is warranted.